Company Focus
Overview
Price Chart
Key Metrics
Valuation
Financials
Earnings
Dividends
Analyst Ratings
Insider Trades
Events Timeline
News + Sentiment
Peer Comparison
Schrodinger
SDGR Small CapHealthcare · Health Information Services
Updated: May 22, 2026, 22:06 UTC
Key Metrics
Valuation Analysis
About the Company
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New
Schrodinger Stock at a Glance
Schrodinger (SDGR) is currently trading at $13.30 with a market capitalization of $993.8M. The 52-week range spans from $10.95 to $27.63; the current price is 51.9% below the yearly high. Year-over-year revenue growth stands at -1.6%.
💰 Dividend
Schrodinger currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
8 analysts rate Schrodinger (SDGR) on consensus: Strong Buy. The average price target is $20.88, implying +56.95% from the current price. Analyst price targets range from $13.00 to $30.00.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 55.33% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 34.13)
- –Revenue shrinking (-1.6% YoY)
- –Currently unprofitable
- –High short interest (24.79%)
- –Negative free cash flow
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to above-average price swings, elevated short interest (24.79%).
Trading Data
Related Stocks in the Same Sector
Schrodinger (SDGR) 2026: 11,95 USD AI-Driven Physics-Based Drug-Discovery Platform with Maestro Software Licensing Recurring Revenue, Internal-Pipeline Optionality, and David Shaw Founder Discipline
The Real Story
Schrodinger Inc. (NASDAQ: SDGR) is a New York-headquartered AI-and-physics-based computational drug-discovery platform founded in 1990 by Richard Friesner and led by founder-investor David Shaw (former co-founder of D.E. Shaw quant-fund). The business operates two revenue streams: Software (approximately 60 percent of revenue, Maestro molecular-modeling, LiveDesign collaborative-platform, plus QSP/PBPK pharmacokinetic-modeling licensed to approximately 1.500 pharma-and-biotech customers including all top-20 global-pharma) and Drug Discovery (approximately 40 percent, internal-pipeline plus strategic-collaboration revenue from Takeda, Otsuka, and other partners).
The structural thesis: Software-licensing recurring-revenue compounds 12-16 percent annually driven by AI-and-physics-based-drug-discovery adoption across pharma-and-biotech R&D; internal-pipeline-asset optionality with multiple Phase 1/2 assets in oncology and immunology including SGR-1505 MALT1-inhibitor for hematologic-malignancies and SGR-2921 CDC7-inhibitor; David Shaw-founder-aligned long-duration capital-allocation discipline.
What Smart Money Thinks
Schrodinger has founder-aligned smart-money base. David Shaw directly and via affiliated entities holds approximately 27 percent — the dominant strategic anchor and quantitative-finance-pioneer providing capital-allocation discipline. Bill Gates via Cascade Investment holds approximately 5 percent. BlackRock at approximately 6,1 percent, Vanguard at approximately 5,2 percent represent passive flows. ARK Invest at approximately 3,8 percent. Short-interest sits at approximately 9 percent of float as of May 2026.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Schrodinger's software-licensing recurring revenue (Maestro, LiveDesign) compounds at approximately 12-16 percent annually with approximately 90 percent gross margin. Net-revenue-retention is approximately 110-115 percent. This segment alone could justify approximately 1,5-2,5 billion USD enterprise value at peer-blended software-multiples.
SGR-1505 MALT1-inhibitor Phase 1 readout 2026, SGR-2921 CDC7-inhibitor Phase 1 readout 2026-2027, plus strategic collaborations with Takeda and Otsuka providing milestone payments. Pipeline optionality alone supports 2-4 USD of risk-adjusted-DCF value per share.
David Shaw's 27 percent ownership plus founder-affiliation provides long-duration capital-allocation discipline. Shaw is a quantitative-finance-pioneer with track-record of long-duration investment-and-capital-discipline through cycle-volatility.
📉 The 3 Real Bear Points
Schrodinger continues to burn approximately 70-100 million USD annually pre-profit. Cash position approximately 300 million USD provides runway through 2027-2028, but additional capital-raise may be required if pipeline-development extends.
SGR-1505 and SGR-2921 Phase 1 readouts in 2026-2027 are binary clinical-trial events. Negative readouts would compress pipeline optionality value.
Software segment faces competition from BIOVIA (Dassault Systemes), OpenEye Scientific, plus emerging AI-drug-discovery startups (Insilico Medicine, Exscientia post-Recursion-merger). Competitive pressure could compress 100-200bps off net-revenue-retention.
Valuation in Context
Schrodinger at 11,95 USD per share with approximately 74,7 million shares outstanding has a market capitalization of approximately 893 million USD. With approximately 300 million USD net cash, enterprise value is approximately 590 million USD against trailing-twelve-month revenue of approximately 240 million USD (approximately 2,5x EV/sales).
Sum-of-the-parts: software-segment at 6-8x revenue (approximately 144M USD software revenue) supports 0,9-1,2 billion USD; pipeline-optionality 200-400 million USD; cash 300 million USD. Total fair-value approximately 1,4-1,9 billion USD or 19-25 USD per share — 60-110 percent upside. Bear-case (pipeline failures) 8-9 USD. Bull-case (positive Phase 1 plus software acceleration) 28-35 USD over 24-36 months.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
Q2 2026 earnings (early August 2026). Watch-items: software-licensing revenue growth, pipeline-development milestone update, collaboration revenue.
-
2026 H2:
SGR-1505 and SGR-2921 Phase 1 interim readouts (expected H2 2026 per management guidance).
-
2027 Q1:
Fiscal-2026 full-year results plus fiscal-2027 guidance. Positive Phase 1 + bullish software guidance would unlock 22-30 USD range.
💬 Daniel's Take
Schrodinger is a AI-physics-based drug-discovery-platform compounder with software-licensing recurring-revenue base, multi-asset internal-pipeline optionality, David Shaw founder-discipline, and sum-of-parts deep-value valuation. Position-sizing: 0,5–1,2 percent in thematic-tech-pharma sleeve, 18–36 month patience.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Schrodinger?
Compare top-rated brokers — low fees, trusted providers, fully regulated.